News | Artificial Intelligence | March 16, 2021

RapidAI Expands AI-powered Vascular Imaging Globally

The RapidAI footprint grew to over 60 countries, with its technology utilized in over 1,800 hospitals

March 16, 2021 — RapidAI, a leader in advanced cerebrovascular imaging, announced record-shattering 2020 milestones for the company and industry, as well as an expansion of its scope into the larger vascular market. As RapidAI momentum built around the world, in addition to new products, partnerships, and awards, 2020 saw the company expand from stroke to aneurysm and lay the groundwork for other vascular diseases, both acute and non-acute. The RapidAI footprint grew to over 60 countries, with its technology utilized in over 1,800 hospitals.

RapidAI offers widely used advanced cerebrovascular imaging products for patient care, research, and clinical trials across the globe. RapidAI clinical products help save lives. In 2020, RapidAI workflow and messaging technologies helped stroke teams save time, and RapidAI analytics and business intelligence products began helping stroke networks reduce costs and improve patient outcomes.

“2020 was such a challenging year for so many around the world, it’s gratifying that our growth and success meant many more lives saved from cerebrovascular disease across dozens of countries,” said Don Listwin, CEO of RapidAI. “Last year we expanded our global footprint, we introduced important new technologies, we helped hospitals understand their businesses better, we made our first strategic acquisition, and we expanded our scope from stroke to include other vascular illnesses, such as aneurysm and pulmonary embolism. With 2020 in the books, we join the world in looking toward a brighter 2021.”

RapidAI Growth:

  • Building on years of profitability, announced a $25 million Series B, to accelerate strategic growth initiatives around the world
  • Acquired EndoVantage and expanded scope to address aneurysm
  • Expanded to 60 countries, including Australia and Argentina
  • Worldwide adoption of the Rapid platform reached 1,800 hospitals
  • Processed more than 1,000,000 stroke imaging scans in 2020 alone, more than a 1,900% increase over 2017
  • Achieved greater than 100% year-over year increase in patients scanned
  • Became RapidAI. The company that leads AI-enhanced stroke imaging around the globe, embraced the future with a new brand and website,
  • Rapid LVO became one of the first software products to qualify for the New Technology Add-on Payment (NTAP), a significant advancement in stroke care reimbursement
  • Launched the RapidAI Technology Partner Program
  • Partnered with Penumbra, for expansion into pulmonary embolism

“RapidAI’s credibility can be assessed from the fact that their solutions are used by over 1,800 hospitals in over 60 countries, and them being profitable since their founding year – an extremely rare occurrence in the imaging AI sector,” said Parth Shah, Senior Research Analyst at Frost & Sullivan. “Not resting on their laurels, in 2020 RapidAI added features to their solutions to address the workflow for stroke interventions, thus providing an end-to-end capability from triaging to intervention. Ultimately this will result in even faster time to treatment, further enhancing patient outcomes and reducing long-term costs.”

RapidAI Innovation:

  • Rapid ASPECTS received Food and Drug Administration (FDA) clearance as the first neuroimaging analysis device in the CADx (Computer-Assisted Diagnostic software) category. Rapid ASPECTS is the only neuroimaging product shown to improve physicians’ interpretations of Non-Contrast CT (NCCT) scans using a standardized ASPECT score
  • RapidAI offered Rapid Aneurysm, a comprehensive aneurysm management platform
  • Rapid LVO received FDA clearance for detecting suspected Large Vessel Occlusions. Rapid LVO helps physicians speed up triage or transfer decision-making
  • Introduced RapidAI Insights, a valuable solution for multi-site systems and referral networks looking to standardize stroke care processes and optimize operational efficiencies that help to reduce costs across sites, while simultaneously improving patient outcomes and saving more lives
  • Launched the Rapid Web App, which offers stroke teams a convenient way to view notifications of new cases, preview Rapid results and source files, and enable workflow communications among team members via their desktop or laptop

RapidAI Awards:

  • RapidAI received the 2020 Global Company of the Year Award from Frost & Sullivan
  • RapidAI won a Minnie. named RapidAI The Best New Radiology Vendor of 2020
  • RapidAI was awarded the 2020 Global Growth, Innovation & Leadership Frost Radar Award

For more information:

Related Content

Videos | Artificial Intelligence | July 22, 2021
This is an overview of trends and technologies in radiology...
This change will be debuted at HIMSS 2021, and Vital will be exhibiting as Canon Medical for the first time
News | Information Technology | July 22, 2021
July 22, 2021 — Canon Medical Systems Corpora
SurveyVitals, a leading patient experience analytics provider, announced it has joined forces with the Radiology Business Management Association (RBMA) to launch Postmarks, a real-time patient and partner feedback software solution
News | Patient Engagement | July 22, 2021
July 22, 2021 — SurveyVitals, a leading patient experie
An example of Viz.AI's pulmonary embolism AI application and mobile alert to the physician on-call. Viz.AI and Avicenna.AI Partner to Launch Artificial Intelligence Care Coordination for Pulmonary Embolism and Aortic Disease

An example of Viz.AI's pulmonary embolism AI application and mobile alert to the physician on-call. 

News | July 21, 2021
July 21, 2021 — Artificial int...
Registration is now open for the Radiological Society of North America (RSNA) 107th Scientific Assembly and Annual Meeting, the world’s largest annual radiology forum, to be held at McCormick Place Chicago, Nov. 28 – Dec. 2, 2021

Getty Images

News | RSNA | July 21, 2021
July 21, 2021 — Registration is now open for the Radiological Society of North America (...
Artificial intelligence-powered diagnostic tool spots asymptomatic prostate cancer in seconds

(L-R) Associate Professor Peter Brotchie (St Vincent's), Dr Ruwan Tennakoon (RMIT), Professor John Thangarajah (RMIT), Dr Mark Page (St Vincent's). Image courtesy of St Vincent's Hospital Melbourne

News | Prostate Cancer | July 19, 2021
July 19, 2021 — Prostate cancer is the most diagnosed